What Trump’s marijuana rescheduling order means for Missouri cannabis

President Trump’s executive order to reschedule cannabis from Schedule I to Schedule III would primarily deliver federal tax relief and formal medical recognition for marijuana, though it will not change interstate commerce restrictions, state license caps, or credit-card banking limits. Missouri operators say the change could allow companies to deduct business expenses previously barred under 280E—potentially boosting profits by roughly 30%—and comes as the state’s market has generated more than $4.5 billion in sales since 2020 and $244.93 million in sales tax revenue in 2024; the rescheduling process is expected to play out in 2026 and leaves significant regulatory and operational constraints in place.

Analysis

Market structure: Rescheduling to Schedule III is a structural positive for U.S. operators and ancillary real‑estate owners because it materially reduces tax drag (280E) and legitimizes banking over time; estimate a 20–35% margin uplift for affected operators if IRS treats rescheduling as removing 280E application. Winners: U.S. MSOs (Curaleaf/CURLF, Green Thumb/GTBIF, Trulieve/TCNNF) and cannabis REIT IIPR; losers: illicit market in the long run and foreign Canadian LPs with limited U.S. asset bases (Canopy/CGC, Tilray/TLRY) if capital rotates to U.S. assets.

Risk assessment: Immediate market reaction will be muted — legal rescheduling process likely through 2026 per article — so material cash flow changes are mostly long‑dated (6–24 months). Tail risks include DOJ/DEA litigation reversal, IRS refusing retrospective 280E relief, Congress imposing a federal excise tax, or banks delaying de‑risking; any of these could erase >50% of expected upside for equities. Hidden dependencies: state license caps (e.g., Missouri) cap addressable growth even with better margins, and inability to cross‑state transport prevents national scale effects.

Trade implications: Tactical trades favor real‑estate and U.S. operator exposure via IIPR (less regulatory execution risk) and MSOS (U.S. MSO ETF) vs global cannabis ETFs that tilt to Canadian LPs (MJ). Use 6–18 month horizon option structures (buy LEAP calls or call spreads) to capture policy realization while limiting downside; target position sizing 1–3% portfolio weight per idea and scale on policy catalysts. Key catalysts: IRS 280E guidance (watch next 30–90 days), DOJ/FDA scheduling publications, and any banking rule changes.

Contrarian angles: Consensus assumes rescheduling equals immediate booming revenue growth — that misses license caps, state regulatory friction, and likely slow bank onboarding. The market may underprice IIPR and ancillary suppliers (horticulture/lighting) relative to operators because rent is sticky and less execution‑risky; conversely some overlevered MSOs may not survive price competition despite tax relief. Historical parallel: partial deregulation episodes (e.g., gambling/online betting rollouts) show policy recognition often precedes multi‑year operational normalization rather than instant profit realization.

Key Decisions for Investors

• Establish a 2–3% long position in Innovative Industrial Properties (IIPR) within 30 days; target a 12–18 month horizon, take profits at +40%, cut at -20% — IIPR gains from more bankable tenants and lower operator distress.
• Deploy 1.5–2% long position in the AdvisorShares Pure US Cannabis ETF (MSOS) to capture U.S. MSO upside; add on pullbacks of ≥15%, target +50% over 12–24 months, stop-loss -25%.
• Implement a pair trade: long MSOS (or GTBIF 1.0–1.5%) and short global cannabis ETF MJ (or CGC 1.0–1.5%) to express U.S. regulatory premium; rebalance if spread moves >15% or after IRS guidance within 60–90 days.
• Buy 12‑month LEAP calls or a 12‑month call spread on IIPR (size 0.5–1% notional) to leverage upside from policy realization while capping premium outlay; close or roll if FDA/DEA publish final rule or if implied vols rise >40%.
• If IRS issues clear retrospective 280E relief within 90 days, increase U.S. MSO exposure by another 1–2% (favor GTBIF/CURLF/TCNNF) and trim non‑U.S. cannabis and speculative ancillary names that already run high leverage.